Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.

Faina NakhlisSamuel M NimanNaoto T UenoElizabeth TrollSean RyanEren YehLaura WarrenJennifer BellonBeth HarrisonToshiaki IwaseH T Carisa Le-PetrossSadia SaleemMediget TeshomeGary J WhitmanWendy A WoodwardBeth OvermoyerSara M TolaneyMeredith ReganFilipa LynceRachel M Layman

Published in: Breast cancer research and treatment (2023)

Among stage III IBC patients, pCR rates were similar, irrespective of the NAC lines number, and BCFS and OS were comparable with pCR after 1L and 2-3L.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
rectal cancer
lymph node
peritoneal dialysis
stem cells
locally advanced
squamous cell carcinoma
bone marrow
real time pcr
mesenchymal stem cells